Venkat Keshamouni, Ph.D.

Associate Professor of Internal Medicine, Pulmonary & Critical Care Division

Research Interests

Deregulation of TGF-beta signaling in lung cancer with a focus on mechanisms of Epithelial-mesenchymal transitions, tumor supression and immune evasion with a goal of identifying therapeutic targets.

Publications

Goswami M, Reka A, Kurapati H, Kaza V, Chen J, Standiford TJ and Keshamouni VG. Regulation of complement-dependent cytotoxicity by TGF-beta-induced epithelial-mesenchymal transition. Oncogene (2015) 00, 1–11. doi:10.1038/onc.2015.258Reka AK, Kurapati H, Narala VR, Bommer G, Chen J, Standiford TJ, Keshamouni VG.  Peroxisome proliferator-activated receptor-{gamma} activation inhibits tumor metastasis  by antagonizing Smad3-mediated epithelial-mesenchymal transition

Mol Cancer Ther. 2010 Dec;9(12):3221-32. PMID: 21159608

Standiford TJ, Kuick R, Bhan U, Chen J, Newstead M, Keshamouni VG.  TGF-β-induced IRAK-M expression in tumor-associated macrophages regulates  lung tumor growth. Oncogene. 2011 Jan 31. [Epub ahead of print] PMID: 21278795

Reka A, Kuick R, Kurapati H, Standiford TJ, Omenn GS, Keshamouni VG.Identifying  Inhibitors of Epithelial-mesenchymal Transition by Connectivity-map Based Systems  Approach. J Thoracic Oncology 2011 Sep 29. [Epub ahead of print] PMID: 21964532

Standiford TJ and Keshamouni VG. Breaking the tolerance or tumor:  Targeting negative regulators of TLR signaling. OncoImmunology 2012 May/Jun; 1 (3): 340-345

Reka A, Chen G, Jones RC, Amunugama R, Kim S, Karnovsky A, Standiford TJ,  Beer DG, Omenn GS, and Keshamouni VG. Epithelial-mesenchymal Transition Associated Secretory Phenotype Predicts Survival in Lung Cancer Patients.
Carcinogenesis 2014; doi: 10.1093/carcin/bgu041

Links

Tags

Tags: